Plassche Douglas
Transaction: 01/09/2026
SELL
Change
-2,500,000
Price
$0.03
Filing
01/13/2026
Type
SELL
Elite Pharmaceuticals, Inc.
ELTP • Drug Manufacturers - Specialty & Generic
$0.26
— 0.00 (0.00%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHLY FAVORABLE PROFILEExcellentConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$293.45M
Growth
6.2%
Cash Flow
3/5
Trend
Mostly stable
Evidence
Stable or improving margins · 30.1%Positive revenue growth · 44.4%Positive free cash flow · 21.27Reasonable earnings multiple · 8.67Manageable debt level · 0.06
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:07 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.26
Change0.00%
Shares Out1.13B
Market Cap$293.45M
Enterprise Value$257.16M
52W Range0.27 - 0.74
Beta0.40
P/E5.18
P/S2.08
P/B2.80
P/FCF-0.32
EV/Sales1.82
Price$0.26
Change0.00%
Shares Out1.13B
Market Cap$293.45M
Enterprise Value$257.16M
52W Range0.27 - 0.74
Beta0.40
P/E5.18
P/S2.08
P/B2.80
P/FCF-0.32
EV/Sales1.82
EV/EBITDA6.18
EV/FCF-0.28
Earnings Yield19.31%
FCF Yield-309.14%
Dividend Yield0.00%
Gross Margin49.36%
Oper. Margin33.56%
Profit Margin30.14%
Debt/Eq0.06
Current Ratio6.45
Quick Ratio-1,215.99
Revenue 5Y6.24%
Volume2.60M
Avg Volume617.43K
EPS Surprise0.15
Investment DNA
How strong this company looks for long-term investors
87
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
85/100
Why this score▼
Stable or improving margins · 30.1%Positive revenue growth · 44.4%Positive free cash flow · 21.27Reasonable earnings multiple · 8.67Manageable debt level · 0.06Healthy liquidity · 6.45
Analyst view
No analyst data available now.
Insider Transactions
Recent executive and insider activity
⚠ 7 high-volume insider sells detected
Plassche Douglas
Transaction: 10/02/2025
SELL
Change
-800,000
Price
$0.62
Filing
10/03/2025
Type
SELL
ELITE PHARMACEUTICALS INC /NV/
Transaction: 08/25/2025
SELL
Change
-2,500,000
Price
$0.03
Filing
08/26/2025
Type
SELL
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Plassche Douglas | SELL | -2,500,000 | $0.03 | 01/09/2026 | 01/13/2026 |
| Plassche Douglas | SELL | -800,000 | $0.62 | 10/02/2025 | 10/03/2025 |
| ELITE PHARMACEUTICALS INC /NV/ | SELL | -2,500,000 | $0.03 | 08/25/2025 | 08/26/2025 |
| ELITE PHARMACEUTICALS INC /NV/ | BUY | +2,500,000 | $0.03 | 08/25/2025 | 08/26/2025 |
| ELITE PHARMACEUTICALS INC /NV/ | SELL | -500,000 | $0.52 | 08/22/2025 | 08/26/2025 |
| Kirkov Kirko | BUY | +16,366 | $0.59 | 07/10/2025 | 07/25/2025 |
| Plassche Douglas | SELL | -200,000 | $0.58 | 07/08/2025 | 07/10/2025 |
| Plassche Douglas | BUY | +2,500,000 | $0.03 | 07/03/2025 | 07/08/2025 |
| Plassche Douglas | SELL | -333,932 | $0.51 | 10/24/2024 | 10/28/2024 |
| Plassche Douglas | SELL | -800,000 | $0.49 | 10/23/2024 | 10/28/2024 |
| Hakim Nasrat A | BUY | +49,534,368 | Not reported | 03/29/2024 | 04/02/2024 |
| Hakim Nasrat A | OTHER | 0 | Not reported | 12/29/2023 | 04/02/2024 |
| Hakim Nasrat A | BUY | +2,223,147 | $0.07 | 12/29/2023 | 12/29/2023 |
| Dash Barry H | BUY | +547,657 | $0.04 | 11/22/2023 | 11/27/2023 |
| Caskey Davis S | BUY | +547,657 | $0.04 | 11/22/2023 | 11/27/2023 |
| WHITNELL JEFFREY A | BUY | +547,657 | $0.04 | 11/22/2023 | 11/27/2023 |
| Plassche Douglas | BUY | +7,500,000 | $0.03 | 01/03/2023 | 06/26/2023 |
| Pellegrino Mark N | OTHER | 0 | Not reported | 05/01/2023 | 05/08/2023 |
| Kirkov Kirko | BUY | +3,000,000 | $0.04 | 09/06/2022 | 11/14/2022 |
| Dash Barry H | BUY | +459,536 | $0.04 | 08/28/2022 | 08/29/2022 |